A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
Summary
The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).
Timeline
- Start
- 2019-02-12
- Primary completion
- 2020-02-27
- Completion
- 2020-02-27
Outcome
Missed primary endpoint
Stopped: “The study was terminated for lack of efficacy after an interim analysis was performed”
registry analysis (superiority test); Placebo vs 50 mg LY3375880; p = 0.638; Odds Ratio (OR) 0.55 (95% CI 0.04 to 6.81); Regression, Logistic NCT03831191 ↗
registry analysis (superiority test); Placebo vs 150 mg LY3375880; p = 0.773; Odds Ratio (OR) 0.69 (95% CI 0.05 to 8.76); Regression, Logistic NCT03831191 ↗
registry analysis (superiority test); Placebo vs 600 mg LY3375880; p = 0.671; Odds Ratio (OR) 0.58 (95% CI 0.05 to 7.26); Regression, Logistic NCT03831191 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TORUDOKIMAB | Monoclonal antibody | 50 mg | Subcutaneous |
| Subject | TORUDOKIMAB | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | TORUDOKIMAB | Monoclonal antibody | 600 mg | Subcutaneous |